L Benvegnù1, M Gios, S Boccato, A Alberti. 1. Department of Clinical and Experimental Medicine, Clinica Medica 5, University of Padova, Padova, Italy. luisa.benvegnu@unipd.it
Abstract
BACKGROUND AND AIMS: The natural history of initially compensated cirrhosis due to hepatitis B (HBV) or hepatitis C (HCV) virus is only partially defined. We have investigated morbidity and mortality rates and the hierarchy of complications in compensated viral cirrhosis over a long follow up period. PATIENTS AND METHODS: A cohort of Italian patients with initially compensated cirrhosis of viral aetiology were followed up at six monthly intervals with laboratory tests to identify major complications (ascites, gastrointestinal bleeding, portal-systemic encephalopathy, hepatocellular carcinoma) and to assess the progression of Child's stage and mortality rate due to liver related causes. RESULTS: Between 1986 and 1996, 312 patients (43 HBV positive, 254 HCV positive, and 15 HBV and HCV coinfected) were included. During a median follow up of 93 (range 14-194) months, 102 (32.6%) patients developed at least one complication (HCV positive 31.1%; HBV positive 34.8%; HBV and HCV coinfected 53.3%). Overall, the most frequent complication was hepatocellular carcinoma which occurred in 65 (20.8%) cases, followed by ascites (61 cases, 19.5%), gastrointestinal bleeding (14 cases, 4.5%), and portal-systemic encephalopathy (six cases, 1.9%). Progression of Child's stage was observed in 62 patients (19.8%). Death from liver disease occurred in 58 (18.6%) cases and in 70.7% this was due to hepatocellular carcinoma. Hepatocellular carcinoma was the first complication to develop in 59 cases and represented the most frequent first complication in both HCV and HBV/ HCV related cirrhosis. CONCLUSIONS: These results indicate significant morbidity and mortality during the first decade after diagnosis of compensated cirrhosis due to HBV and/or HCV, and identify hepatocellular carcinoma as the most frequent and life threatening complication, particularly in HCV positive cases.
BACKGROUND AND AIMS: The natural history of initially compensated cirrhosis due to hepatitis B (HBV) or hepatitis C (HCV) virus is only partially defined. We have investigated morbidity and mortality rates and the hierarchy of complications in compensated viral cirrhosis over a long follow up period. PATIENTS AND METHODS: A cohort of Italian patients with initially compensated cirrhosis of viral aetiology were followed up at six monthly intervals with laboratory tests to identify major complications (ascites, gastrointestinal bleeding, portal-systemic encephalopathy, hepatocellular carcinoma) and to assess the progression of Child's stage and mortality rate due to liver related causes. RESULTS: Between 1986 and 1996, 312 patients (43 HBV positive, 254 HCV positive, and 15 HBV and HCV coinfected) were included. During a median follow up of 93 (range 14-194) months, 102 (32.6%) patients developed at least one complication (HCV positive 31.1%; HBV positive 34.8%; HBV and HCV coinfected 53.3%). Overall, the most frequent complication was hepatocellular carcinoma which occurred in 65 (20.8%) cases, followed by ascites (61 cases, 19.5%), gastrointestinal bleeding (14 cases, 4.5%), and portal-systemic encephalopathy (six cases, 1.9%). Progression of Child's stage was observed in 62 patients (19.8%). Death from liver disease occurred in 58 (18.6%) cases and in 70.7% this was due to hepatocellular carcinoma. Hepatocellular carcinoma was the first complication to develop in 59 cases and represented the most frequent first complication in both HCV and HBV/ HCV related cirrhosis. CONCLUSIONS: These results indicate significant morbidity and mortality during the first decade after diagnosis of compensated cirrhosis due to HBV and/or HCV, and identify hepatocellular carcinoma as the most frequent and life threatening complication, particularly in HCV positive cases.
Authors: S Zeuzem; S V Feinman; J Rasenack; E J Heathcote; M Y Lai; E Gane; J O'Grady; J Reichen; M Diago; A Lin; J Hoffman; M J Brunda Journal: N Engl J Med Date: 2000-12-07 Impact factor: 91.245
Authors: E J Heathcote; M L Shiffman; W G Cooksley; G M Dusheiko; S S Lee; L Balart; R Reindollar; R K Reddy; T L Wright; A Lin; J Hoffman; J De Pamphilis Journal: N Engl J Med Date: 2000-12-07 Impact factor: 91.245
Authors: V Di Marco; O Lo Iacono; C Cammà; A Vaccaro; M Giunta; G Martorana; P Fuschi; P L Almasio; A Craxì Journal: Hepatology Date: 1999-07 Impact factor: 17.425
Authors: H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki Journal: N Engl J Med Date: 1993-06-24 Impact factor: 91.245
Authors: Do Young Kim; Seung Up Kim; Sang Hoon Ahn; Jun Yong Park; Jung Min Lee; Young Nyun Park; Ki Tae Yoon; Yong Han Paik; Kwan Sik Lee; Chae Yoon Chon; Kwang-Hyub Han Journal: Dig Dis Sci Date: 2008-11-13 Impact factor: 3.199
Authors: Cristiane Valle Tovo; Angelo Alves de Mattos; Paulo Roberto Lerias de Almeida Journal: World J Gastroenterol Date: 2014-03-21 Impact factor: 5.742